Baxter price target lowered to $19 from $21 at UBS

UBS analyst Danielle Antalffy lowered the firm’s price target on Baxter (BAX) to $19 from $21 and keeps a Neutral rating on the shares. The firm sees limited near-term visibility for Baxter after the company’s 2026 outlook “underwhelms.”